Show simple item record

dc.contributor.authorAstor, Marianneen_US
dc.contributor.authorLøvås, Kristianen_US
dc.contributor.authorDebowska, Aleksandraen_US
dc.contributor.authorEriksen, Erik Finken_US
dc.contributor.authorEvang, Johan Arilden_US
dc.contributor.authorFossum, Jan Christianen_US
dc.contributor.authorFougner, Kristian Jen_US
dc.contributor.authorHolte, Synnøve E.en_US
dc.contributor.authorLima, Karien_US
dc.contributor.authorMoe, Ragnar Bekkhusen_US
dc.contributor.authorMyhre, Anne Gretheen_US
dc.contributor.authorKemp, E. Helenen_US
dc.contributor.authorNedrebø, Bjørn Gunnaren_US
dc.contributor.authorSvartberg, Johanen_US
dc.contributor.authorHusebye, Eystein Sverreen_US
dc.PublishedJournal of Clinical Endocrinology and Metabolism 2016, 101(8):3045-3053eng
dc.description.abstractObjective: The epidemiology of hypoparathyroidism (HP) is largely unknown. We aimed to determine prevalence, etiologies, health related quality of life (HRQOL) and treatment pattern of HP. Methods: Patients with HP and 22q11 deletion syndrome (DiGeorge syndrome) were identified in electronic hospital registries. All identified patients were invited to participate in a survey. Among patients who responded, HRQOL was determined by Short Form 36 and Hospital Anxiety and Depression scale. Autoantibodies were measured and candidate genes (CaSR, AIRE, GATA3, and 22q11-deletion) were sequenced for classification of etiology. Results: We identified 522 patients (511 alive) and estimated overall prevalence at 102 per million divided among postsurgical HP (64 per million), nonsurgical HP (30 per million), and pseudo-HP (8 per million). Nonsurgical HP comprised autosomal dominant hypocalcemia (21%), autoimmune polyendocrine syndrome type 1 (17%), DiGeorge/22q11 deletion syndrome (15%), idiopathic HP (44%), and others (4%). Among the 283 respondents (median age, 53 years [range, 9–89], 75% females), seven formerly classified as idiopathic were reclassified after genetic and immunological analyses, whereas 26(37%of nonsurgical HP) remained idiopathic. Most were treated with vitamin D (94%) and calcium (70%), and 10 received PTH. HP patients scored significantly worse than the normative population on Short Form 36 and Hospital Anxiety and Depression scale; patients with postsurgical scored worse than those with nonsurgical HP and pseudo-HP, especially on physical health. Conclusions: We found higher prevalence of nonsurgical HP in Norway than reported elsewhere. Genetic testing and autoimmunity screening of idiopathic HP identified a specific cause in 21%. Further research is necessary to unravel the causes of idiopathic HP and to improve the reduced HRQOL reported by HP patients.en_US
dc.publisherEndocrine Societyeng
dc.rightsAttribution CC BY-NCeng
dc.titleEpidemiology and health related quality of life in hypoparathyroidism in Norwayen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2016 Endocrine Society

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY-NC
Except where otherwise noted, this item's license is described as Attribution CC BY-NC